Iterum Therapeutics (ITRM)
(Delayed Data from NSDQ)
$1.06 USD
-0.04 (-3.21%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $1.07 +0.02 (1.42%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Iterum Therapeutics PLC [ITRM]
Reports for Purchase
Showing records 1 - 20 ( 74 total )
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
2Q Recap: September 9 AdCom to Weigh Sulopenem''s U.S. Approval By October 25 PDUFA Date; Moderating PT to $5 on Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
AdCom Scheduled on September 9 to Determine Sulopenem''s Specific Use For Treating uUTI; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
1Q Recap: Awaiting PDUFA Date Assignment For Sulopenem''s NDA Resubmission For uUTI
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
NDA Resubmission of Sulopenem in uUTI Sets The Stage For Its First U.S. Approval in Early 4Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
4Q Recap; Sulopenem uUTI NDA Resubmission On Target in Early 2Q24; PDUFA Date Expected in Early 4Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Sulopenem uUTI NDA Resubmission Pulled Forward to First Half of 2Q24; Cash Runway Extends Into 2025; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Phase 3 REASSURE uUTI Study Is a Resounding Success; NDA Resubmission in 2Q24; Upgrading to Buy with $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
3Q Recap; REASSURE Top-Line Data Readout in Early 1Q24 to Determine Sulopenem''s Path Forward; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
REASSURE Completes Enrollment; Sulopenem''s NDA Resubmission For uUTI Expected in 2Q24; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
2Q Recap; Phase 3 REASSURE uUTI Study Now 50% Enrolled; Top-line Data Now Expected in 2Q24; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
1Q Recap; Pivotal Phase 3 uUTI Study on Target For Complete Enrollment in 1H24; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
4Q Recap; Top-line Data From REASSURE Study in Mid-2024 Assumes No Adjustments at Interim Analysis; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
3Q Recap; Phase 3 REASSURE Sulopenem uUTI Study Begins; Composition Patent Extends IP to 2039; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
New Phase 3 REASSURE Trial of Sulopenem in uUTI Initiated; NDA Resubmission Expected in 2H24; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Sulopenem U.S. IP Protection Extends to 2039; New Phase 3 Study to Begin Enrollment Within Weeks; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
2Q Recap; New Sulopenem Pivotal uUTI Study''s Initiation On Target in 4Q22; Awaiting Firmer Timeline; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
FDA Agrees to New Phase 3 Study of Oral Sulopenem Under a SPA; Trial Initiation Expected in 4Q22; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
1Q Recap; Awaiting Details of New Phase 3 Trial of Sulopenem For uUTI; Cash Runway Extends Into 2024; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E